首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   13233篇
  免费   1168篇
  国内免费   7篇
  2021年   164篇
  2020年   89篇
  2019年   149篇
  2018年   135篇
  2017年   121篇
  2016年   266篇
  2015年   454篇
  2014年   506篇
  2013年   699篇
  2012年   828篇
  2011年   847篇
  2010年   539篇
  2009年   517篇
  2008年   737篇
  2007年   740篇
  2006年   650篇
  2005年   711篇
  2004年   685篇
  2003年   619篇
  2002年   610篇
  2001年   123篇
  2000年   101篇
  1999年   126篇
  1998年   173篇
  1997年   115篇
  1996年   88篇
  1995年   95篇
  1994年   95篇
  1993年   91篇
  1992年   102篇
  1991年   89篇
  1990年   90篇
  1989年   78篇
  1988年   79篇
  1987年   88篇
  1986年   87篇
  1985年   85篇
  1984年   128篇
  1983年   108篇
  1982年   127篇
  1981年   135篇
  1980年   147篇
  1979年   118篇
  1978年   115篇
  1977年   111篇
  1976年   91篇
  1975年   87篇
  1974年   98篇
  1973年   76篇
  1969年   64篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH1-34) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH1-34 has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction osteogenesis. These studies have demonstrated that intermittent PTH1-34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH1-34 has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH1-34 treatment of delayed-unions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH1-34 treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the appropriate patient population for PTH1-34 therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH1-34 therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications) and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering.  相似文献   
2.
3.
4.
5.
6.
7.
8.
In the American lobster (Homarus americanus) the biogenic amines serotonin and octopamine appear to play important and opposite roles in the regulation of aggressive behavior, in the establishment and/or maintenance of dominant and subordinate behavioral states and in the modulation of the associated postural stances and escape responses. The octopamine-containing neurosecretory neurons in the thoracic regions of the lobster ventral nerve cord fall into two morphological subgroups, the root octopamine cells, a classical neurohemal group with release regions along second thoracic roots, and the claw octopamine cells, a group that selectively innervates the claws. Cells of both subgroups have additional sets of endings within neuropil regions of ganglia of the ventral nerve cord. Octopamine neurosecretory neurons generally are silent, but when spontaneously active or when activated, they show large overshooting action potentials with prominent after-hyperpolarizations. Autoinhibition after high-frequency firing, which is also seen in other crustacean neurosecretory cells, is readily apparent in these cells. The cells show no spontaneous synaptic activity, but appear to be excited by a unitary source. Stimulation of lateral or medial giant axons, which excite serotonergic cells yielded no response in octopaminergic neurosecretory cells and no evidence for direct interactions between pairs of octopamine neurons, or between the octopaminergic and the serotonergic sets of neurosecretory neurons was found.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号